Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.
This is an open-label trial with two phases. In Phase 1, participants will receive EMB-02 one weekly (intravenously) at ascending dose levels. In Phase II, participants will receive EMB-02 weekly (intravenously) at the recommended Phase 2 dose (RP2D).